Alectinib Dose Escalation Re-induces Central Nervous System Responses in ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients Relapsing on Standard Dose Alectinib

The central nervous system (CNS) is an important and increasingly recognized site of treatment failure in ALK-positive, non-small cell lung cancer (NSCLC) patients receiving ALK inhibitors. In this report, we describe two ALK-positive patients who experienced initial improvements in CNS metastases o...

Full description

Saved in:
Bibliographic Details
Published in:J Thorac Oncol
Main Authors: Gainor, Justin F., Chi, Andrew S., Logan, Jennifer, Hu, Ranliang, Oh, Kevin S., Brastianos, Priscilla K., Shih, Helen A., Shaw, Alice T.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4743545/
https://ncbi.nlm.nih.gov/pubmed/26845119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2015.10.010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items